| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary biological target is the steroidogenic pathway and nuclear receptor signaling. 22R-OHC is a substrate for CYP11A1 in the first step of steroidogenesis and can modulate LXR and other nuclear receptors; its biological effects are mediated by enzymatic conversion to steroids and by receptor-mediated signaling. The deuterated standard is used as an analytical surrogate for 22R-OHC quantification and does not modulate steroidogenic enzymes or nuclear receptors.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [2].
The d7-labeled standard shows no measurable intrinsic bioactivity and is not used for potency screening. Endogenous 22R-OHC is a low-abundance oxysterol that requires a structurally matched internal standard for accurate quantification; the d7 form co-elutes with the analyte and corrects for extraction recovery, ionization efficiency, and matrix effects during oxysterol analysis. |
| ln Vivo |
No intrinsic in vivo pharmacological activity has been reported for the deuterated standard. Endogenous 22R-OHC is a steroidogenic intermediate and a modulator of nuclear receptor signaling; the d7 standard supports in vivo quantification of 22R-OHC in adrenal tissue and plasma and enables studies of steroidogenesis and oxysterol signaling in animal models.
|
| Enzyme Assay |
LC-MS/MS oxysterol quantification: add 22(R)-Hydroxycholesterol-d7 to the sample before saponification and extraction; extract sterols with organic solvent; derivatize if required; separate on a reversed-phase C18 column; monitor the specific m/z transition of the d7 standard and the corresponding unlabeled oxysterol transition. Quantification is by isotope-dilution calibration using peak-area ratios.
|
| Cell Assay |
Cell-based steroidogenic and oxysterol profiling: culture adrenal or steroidogenic cells under conditions that modulate steroidogenesis, harvest and quench metabolism, add the d7 internal standard, extract sterols, and analyze by LC-MS/MS.
|
| Animal Protocol |
In vivo adrenal and plasma oxysterol analysis: collect adrenal tissue or plasma at defined time points, add 22(R)-Hydroxycholesterol-d7 before homogenization, saponify and extract sterols, and quantify by LC-MS/MS to assess steroidogenic flux and oxysterol levels in animal models.
|
| References |
| Molecular Formula |
C27O2H46
|
|---|---|
| Molecular Weight |
409.6961
|
| Exact Mass |
409.393
|
| CAS # |
1246302-93-1
|
| Related CAS # |
22(R)-Hydroxycholesterol;17954-98-2
|
| PubChem CID |
42608391
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
513.1±23.0 °C at 760 mmHg
|
| Flash Point |
213.5±17.2 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.536
|
| LogP |
7.66
|
| tPSA |
40.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
624
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
O[C@H](CCC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@@]21C)O
|
| InChi Key |
RZPAXNJLEKLXNO-VBPFJDFISA-N
|
| InChi Code |
InChI=1S/C27H46O2/c1-17(2)6-11-25(29)18(3)22-9-10-23-21-8-7-19-16-20(28)12-14-26(19,4)24(21)13-15-27(22,23)5/h7,17-18,20-25,28-29H,6,8-16H2,1-5H3/t18-,20-,21-,22+,23-,24-,25+,26-,27+/m0/s1/i1D3,2D3,17D
|
| Chemical Name |
(3S,8S,9S,10R,13S,14S,17R)-10,13-dimethyl-17-[(2S,3R)-6,7,7,7-tetradeuterio-3-hydroxy-6-(trideuteriomethyl)heptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4408 mL | 12.2041 mL | 24.4081 mL | |
| 5 mM | 0.4882 mL | 2.4408 mL | 4.8816 mL | |
| 10 mM | 0.2441 mL | 1.2204 mL | 2.4408 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
